In NSCLC tumor tissues, IL-33 is robustly expressed in cancer cells while ST2 is expressed on both cancer cells and infiltrated lymphocytes [20], indicating IL-33 as a dual-function factor that could affect both NSCLC cells and immune surveillance in tumor microenvironments. The gene discussed is IL33; the disease is cancer.